See "Focused therapies in CLL: mechanisms of resistance and techniques for management" on web page 471. Duvelisib was the 2nd PI3K inhibitor permitted because of the FDA, also according to a phase III randomized demo.130 The efficacy and protection profile with the drug seem equivalent with those of idelalisib, if https://shanelyjrz.blogzag.com/76416718/link-alternatif-mbl77-an-overview